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1. Our Editorial vision for Cardiovascular Research 
Cardiovascular Research, which recently celebrated its 50-year anniversary of service to the 
cardiovascular community, strives to be recognized as the number one journal for basic and  
translational cardiovascular research (1). Our major goal is to foster productive interactions between 
basic and clinical cardiovascular scientists worldwide. This mission is based on the Journal’s motto: 
“scientific discovery drives clinical delivery”.   
We strive to publish original and innovative basic, translational, and clinical research that 
enhances the understanding of disease mechanisms and identifies or validates new therapeutic 
targets. We welcome and encourage submissions from across the globe, recognizing the worldwide 
growth in excellent cardiovascular research. We provide rapid, detailed and professional assessment 
of manuscripts with an emphasis on originality; mechanistic insight; impact; methodological 
robustness; translational potential and reproducibility (Figure 1A).   
Cardiovascular Research is the European Society of Cardiology’s (ESC) flagship journal for basic 
and translational cardiovascular research. As such, we aim to establish strong partnerships with the 
ESC Working Groups and Councils (2-8) and with researchers at the forefront of the cardiovascular 
field. We foster a supportive environment for investigators and bring our readers the most relevant 
discoveries. To this end, we also aim to actively promote and support young investigators through 
our close partnerships with the ESC Scientists of Tomorrow (9).  
Our aspiration is to be truly interdisciplinary. To this end, our Deputy and Associate Editors and 
Editorial Board members represent all major cardiovascular sub-specialities. Cardiovascular Research 
should not be considered a “cardiomyocyte journal” or a “Vascular Journal”, but one that welcomes 
all relevant science. Expanding the Journal’s global presence is a key aim of the new Editorial team. 
We have actively sought the involvement of scientific world-leaders from over 20 different countries 
within Europe and beyond, including Asia, Australia, Canada and the United States.  
The Editorial team is honoured to represent the Journal at major international conferences, 
including the main ESC Congress and  Frontiers in Cardiovascular Biology (FCVB) (10). We also 
welcome the opportunity to interact with international researchers and potential authors at 
meetings such as the Oriental Conference of Cardiology, International Society of Heart Research, 
European and International Vascular Biology Societies, European Society for Microcirculation and 
the American Heart Association (AHA) meetings.  
2. Scope of submissions – strengths and opportunities 
 We are delighted to see an increase in the Journal’s Impact Factor, now standing at 6.29, the 
highest ever. We are optimistic that this will increase substantially in the next several years. 
Submissions to the Journal have increased such that we expect to handle approximately 1400 papers 
in 2018. We take this opportunity to thank all the authors who have submitted manuscripts to us. 
Cardiovascular Research will continue to focus on its traditional areas of strength, whilst branching 
out into previously under-represented fields (Figure 1B). The Journal will place a renewed focus on 
the translational application of basic science discovery to ensure Cardiovascular Research stays 
relevant in an increasingly cross-disciplinary field. The Editors recognise that the translation of basic 
research is the ultimate goal, but we realize that this translation often takes many years. We 
therefore also seek to publish promising basic discoveries that have yet to reach the stage of 
translation. 
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3. Maximising the visibility and impact of your research 
Cardiovascular Research will make every effort to ensure that each published manuscript 
receives maximum exposure. In addition to the Journal’s global readership (over 2 million downloads 
per year and over 22,000 total citations in 2017), through our close working relationship with the 
ESC and Oxford University Press (OUP) we can offer several highly effective platforms for maximising 
the visibility and impact of your research. Papers published in the Journal benefit from social media 
promotion through the OUP and ESC twitter (80,000 followers and counting). Articles of broad 
scientific interest can be highlighted in an Oxford University Press blog (OUPblog) in medicine (11) or 
through worldwide press releases (12). These receive wide mainstream media attention and attract 
high Altmetric scores.  In addition, papers of high impact for the cardiovascular field can be included 
within the MyESC newsletter, reaching over 70,000 subscribers. 
Articles published with the Journal are placed in Advanced Access on our website within two 
weeks of acceptance and can be accessed via the ESC Journals App. Within each issue, selected 
“Editor’s Choice” articles are made freely accessible. Every year, Cardiovascular Research Onlife will 
publish a list of the 20 most read articles published in the Journal. This service will acknowledge the 
outstanding contribution of our authors but also provide to our readership an overview of the hot 
topics in cardiovascular research. Another vehicle for recognising the contribution of our authors will 
be the newly formed “Best Cardiovascular Research Paper Prize” that will be awarded for the first 
time at the ESC Congress in 2018. 
4. Unique features in Cardiovascular Research 
Cardiovascular Research authors and readers will notice several changes when viewing our 
new table of contents. To increase the manuscripts’ visibility and dissemination, the Editorial Office 
now requests a graphical abstract from authors to feature in the online table of contents. 
Subsections are now present in the table of contents to highlight the expanded portfolio of topics 
published in the Journal. Finally, to diversify the Journal’s content and enrich the experience of our 
readers, the Editorial team are excited to introduce new article types. 
4.1. Science in Practice: Methods and Scientific Guidelines 
The Journal is known for its focus on scientific rigor and robust methodology; to promote this 
further, the Editorial team will invite a committee of experts to produce Methodological Protocols 
and Guidelines for Basic and Translational Scientific Research. This is also in response to a strong 
feeling amongst the cardiovascular research community that such guidelines are needed. These will 
be prepared together with the ESC Council for Basic Cardiovascular Sciences. Furthermore, the 
Editorial Team actively appeals to Working Groups to consider Cardiovascular Research as the place 
to disseminate position statements related to newly developed research techniques. From all 
investigators, Cardiovascular Research will continue to consider manuscripts that describe new 
methodologies and research tools that have the potential to greatly influence their respective field, 
generate novel ideas, and find broad application to cardiovascular science and beyond. 
4.2. Research Letters and Fast-track Communications 
“Research Letters” are a new manuscript category of the Journal, created to meet the need for 
rapid dissemination of novel findings with high translational potential. A further new manuscript 
category, “Fast-track Communications”, will offer a slightly longer format for rapid publication of 
high scientific priority findings. We will rely on our Fast Track Reviewers and Editorial Board 
Members to help in ensuring a particularly rapid peer-review process. The guidelines for preparing a 
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Research Letter or Fast-track Communication are given in the updated online Instructions for 
Authors. 
4.3 Clinical and Translational Research 
The new Editorial Team is extending the scope of Cardiovascular Research to include high-quality 
mechanistic studies in humans. We will launch a designated “Clinical/Translational Cardiovascular 
Research Section” within the Journal where the Editorial Team will actively seek high quality studies 
that are either well-designed clinical studies with mechanistic insights or genuinely bench-to-bedside 
studies using mixed clinical and basic science approaches. This section is being developed in close 
collaboration with European Heart Journal and other Journals of the ESC family. We strongly 
encourage submissions of epidemiological or genetic studies that identify new targets or biomarkers 
that may warrant further mechanistic interrogation by basic research. Mendelian Randomization 
studies are also welcome.  
4.4 Expedited handling of Manuscripts transferred from EHJ 
The Journal takes advantage of our strong relationship with the ESC family of journals, including 
the European Heart Journal, by providing expedited handling for authors who wish to transfer their 
basic or translational manuscripts to Cardiovascular Research. This has many benefits for the author 
including the potential to publish their work faster, without the need to reformat their submission 
and their work remaining within the highly prestigious ESC Journal family. For these manuscripts we 
typically rely on existing reviews and a detailed formal review and assessment from a Cardiovascular 
Research handling editor. In some circumstances, we will consider transfers from journals outside 
the ESC family. 
4.5 Review articles and Spotlight Issues 
Cardiovascular Research welcomes the submission of high quality review articles; the Editorial 
Team encourages potential authors to send a pre-submission enquiry and short table of content to 
the Editorial Office. The Editors expect that Review Articles will link basic findings to potential clinical 
application. We strongly encourage a systematic review to support the conclusions of Review 
Articles. We will also continue to commission state of the art Review Articles from key opinion 
leaders and publish Spotlight Issues on hot topics in cardiovascular research. Our recent Spotlight 
Issue on Smooth Muscle Cell Biology brought together authors from over ten countries with 
expertise ranging from epigenetics to cell plasticity (13). For commissioned Review Articles, we offer 
an excellent medical illustrations service to create figures that summarise the main messages of the 
article.  
5. Cardiovascular Research Onlife 
Supporting young investigators is a major goal of the ESC. As part of the ESC Journals family, 
Cardiovascular Research fully supports this mission. One way in which the Journal has done this is 
through its Cardiovascular Research Onlife platform launched in April 2017 in collaboration with the 
ESC Scientists of Tomorrow (14). This is a portion of journal that includes articles co-authored by 
young investigators and a more senior author. The Clinical Commentaries and Editor’s Corner 
sections provide succinct, high quality summaries of recent practice-changing clinical trials and hot 
topics that have implications for clinical and basic investigation. In collaboration with the ESC 
Scientists of Tomorrow, the “Spotted by the Scientists of Tomorrow” feature highlights recent high 
impact non-cardiovascular studies that have implications for cardiovascular research (15). In 
addition, the ESC Scientists of Tomorrow participate in the “Scientists on the Spot” initiative, where 
the Journal records short video interviews with top cardiovascular Scientists about novel techniques 
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and hot topics in Cardiovascular Medicine. The Editor-in-Chief also records a set of interviews with 
iconic figures of Cardiovascular Sciences, in a new “Cardiovascular Research Colloquia” category. 
These short and often inspiring conversations are being presented as videos on our website and 
published in print within Cardiovascular Research Onlife. 
6. Conclusion 
In conclusion our aim is to build upon an excellent reputation for scientific rigor and quality, 
developing into a reliable and stimulating platform for the exchange of scientific knowledge 
attracting the highest impact cardiovascular publications. As one of the European Society of 
Cardiology’s (ESC) most important assets, our ambition is to serve as a bridge between basic science 
and clinical research, while maintaining focus on high quality basic discovery.  
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Figure Legend 
Figure 1: What we publish in Cardiovascular Research. Panel (A) delineates the main features we 
seek in manuscripts submitted to Cardiovascular Research. Panel (B) describes the areas of strength 
and potential for growth identified by the Editorial team; the Journal encourages submissions from 
these topics 
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Figure
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Cardioprotection
Right ventricle and pulmonary circulation
Vascular biology
A
Originality
Mechanistic 
Insight
Impactful
Robust 
Methodology
Reproducibility
Translational 
Potential
B
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